Posts

Acting FDA chief isn't interested in permanent role: Key facts Kyle Diamantas, an attorney who previously led the FDA's food program, has been named acting commissioner of the Food and Drug Administration following the resignation of Commissioner Marty Makary. Diamantas is stepping in on an interim basis while the administration searches for a permanent replacement, who will need to be nominated by the President and confirmed by the Senate. Reports indicate that Diamantas is viewed as a steady hand to manage the agency through this transition. There is no indication that Diamantas is seeking the permanent role, suggesting that he is not interested in becoming the next permanent FDA commissioner.

on
Kyle Diamantas, the FDA's chief for foods, will take over as acting commissioner as Makary's streamlining initiatives face an uncertain future, lacking the permanent regulatory changes needed for survival. A permanent replacement for FDA commissioner will need to be nominated by Trump and confirmed by a majority vote in the Senate. Sources: FDA chief Marty Makary resigns from agency, ending tumultuous ... FDA Makes Leadership Overhaul Following Commissioner Makary's ... FDA Welcomes Dr. Martin A. Makary as 27th Commissioner of Food ... Former FDA chief reacts to worrisome layoffs at HHS - YouTube FDA Commissioner FDA Overview- Text Version FDA chief resigns without warning - PMC - NIH FDA's Makary Resigns With Agency in Turmoil - YouTube FDA Leadership Chart [PDF] how one bad sentence in the cures act blocked fda's cancer center ... Trump FDA chief is leaving after angering pharma CEOs, vaping ... Commissioners - FDA Commissioner of Food ...

Medline Faces FDA Warning Over Repeat *Bacillus cereus* Contamination in Drug Products

on

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

on

Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

on

ADC Therapeutics shares sink over 50% after Phase 3 Zynlonta trial shows more deaths than standard therapy

on

As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Recent efforts in Washington to restrict U.S. investment and partnerships with Chinese biotech firms have triggered a fierce backlash from industry leaders and intensified concerns in Beijing, turning biotech into the latest front in the U.S.-China tech rivalry.

on

AbbVie’s QULIPTA and Amgen’s Imdylltra Score New EU Approvals for Migraine and Lung Cancer Indications

on

Real-world patterns of Alzheimer’s disease biomarker testing: Insights from a large-scale clinical dataset (Overview, 2026)

on

Germany’s Health‑Spending Cuts Prompt Lilly and Boehringer to Scale Back German Investments

on

Regeneron doubles down on CytomX despite other pharma exits, expanding pact to up to ~$4 billion potential value

on

ChatGPT and other LLMs for cancer patient education: help or hindrance?

on

Ascidian and Lilly Ink Up‑to‑$1.9B Pact for RNA Exon Editing in Genetic Kidney Diseases

on

Akeso takes center stage at ASCO 2026 as China biotech cements its global arrival

on